State-owned enterprise Guoyao Modern: wholly-owned subsidiary injectable piperacillin sodium passes generic drug consistency evaluation.

China National Pharmaceutical Group announced that its wholly-owned subsidiary, China National Pharmaceutical Weiqida, has received notification that the injection of piperacillin sodium has added a 1.0g specification and 0.5g, 1.0g, and 2.0g specifications have passed generic drug consistency evaluation. This drug is suitable for various infections. According to Minet data, its sales in public medical institutions nationwide are expected to reach approximately 1.906 billion yuan by 2024. Currently, there are several enterprises with the same specifications products passing/gaining consistency evaluation. China National Pharmaceutical Weiqida has cumulatively invested approximately 6.12 million yuan in research and development. The addition of new specifications and passing the evaluation will benefit the expansion of the product market, but drug sales are influenced by multiple factors, leading to uncertainty.